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Unitermos: acute diffuse otitis externa, ciprofloxacin 2 mg/mL, hydrocortisone 10 mg/mL, otologic suspension.
Unterms: otite externa aguda difusa, ciprofloxacino 2 mg/mL, hidrocortisona 10 mg/mL, suspensão otológica.
Su m ár i o
This was Phase III multicenter, double-blind, randomized, comparative safety and efficacy study in parallel groups of subjects,
assessing non-inferiority between two commercially available otologic suspensions containing ciprofloxacin 2mg/mL and
hydrocortisone 10mg/mL (Otociriax and Cipro HC®) in the treatment of acute diffuse otitis externa. Following screening and
informed consent, subjects were randomly allocated into two treatment groups: Group A (treated with Otociriax) and Group B
(treated with Cipro HC®). Treatment regimen in both groups was three drops, twice daily for seven days. The primary study
endpoint was otitis cure, defined as elimination of pain, edema, and otorrhea. The secondary study endpoint was presence of side
effects. Efficacy assessments included presence and intensity of otitis externa manifestations. Safety assessments included vital
signs and physical examination, as well as adverse event monitoring. Study data analysis was performed using GraphPad Prism 5.0.
For categorical variables, we used the c2 or Fisher’s test, while continuous variables were analyzed using the ANOVA or Student’s T
test. A total of 265 subjects were randomized to treatment, with 132 subjects in Group A and 133 in Group B. There were no
statistically significant pretreatment differences between the two treatment groups (p>0.05 for all variables). All subjects presented
manifestations of acute diffuse otitis externa at pretreatment. There were statistically significant improvements (p<0.05) in each
parameter of otitis externa assessed in both treatment groups. At the end of the treatment period, 96 (82.05%) subjects in Group
A and 100 subjects (86.97%) in Group B were completely symptom-free, with no statistically significant difference between
treatment groups in symptom remission (c2=2.147; df=3; p=0.542). Overall, no unfavorable alteration was detected in the safety
parameters monitored, in either treatment group. Adverse events were reported among 11 subjects in Group A and 7 subjects in
Group B. There was no statistically significant between-group difference in incidence (p=0.463), duration (c2=13.55; df=7;
p=0.06), or distribution of causality assessment (p=0.4) of the adverse events. The results of this study clearly indicate that there
was no difference in treatment results between the two patient groups. Both treatments were safe and effective in treating the
signs and symptoms of otitis externa as evidenced by the assessments performed throughout the treatment period. Treatment with
Otociriax was non-inferior to treatment with Cipro HC® in the patient population evaluated in this study.
Su m ar y
Este foi um estudo Fase III multicêntrico, duplo-cego, randomizado e comparativo de segurança e eficácia em grupos paralelos de
pacientes, avaliando a não-inferioridade entre duas suspensões otológicos disponíveis comercialmente contendo ciprofloxacina 2
mg/ml e hidrocortisona 10 mg/mL (Otociriax e Cipro HC®), no tratamento da otite externa aguda difusa. Após a triagem e
consentimento informado, os indivíduos foram alocados aleatoriamente entre dois grupos de tratamento: Grupo A (tratado com
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Otociriax) e Grupo B (tratado com Cipro HC®). O regime de tratamento em ambos os grupos foi de três gotas, duas vezes por dia
durante sete dias. O desfecho primário do estudo foi a cura da otite, definida como eliminação da dor, edema, e otorreia. O
desfecho secundário foi a presença de efeitos colaterais. A avaliação de eficácia incluiu a presença e intensidade das manifestações
de otite externa. As avaliações de segurança incluíram sinais vitais e exame físico, bem como o monitoramento de eventos
adversos. A análise dos dados do estudo foi realizada utilizando GraphPad Prism 5.0. Para as variáveis categóricas, foi utilizado o
teste c2 ou teste de Fisher, enquanto as variáveis contínuas foram analisadas usando o ANOVA ou teste T de Student. Um total de
265 indivíduos foram randomizados para o tratamento, com 132 indivíduos no grupo A e 133 no Grupo B. Não houve diferenças
pré-tratamento estatisticamente significativas entre os dois grupos de tratamento (p>0,05 para todas as variáveis). Todos os
sujeitos apresentaram manifestações da otite externa aguda difusa no pré-tratamento. Houve melhora estatisticamente significativa
(p<0,05) em cada parâmetro de otite externa avaliada em ambos os grupos de tratamento. No final do período de tratamento, 96
(82,05%) indivíduos do grupo A e 100 indivíduos (86,97%) no grupo B estavam completamente livre de sintomas, não havendo
diferença estatisticamente significativa entre os grupos de tratamento na remissão dos sintomas (c2=2,147; df=3; p=0,542). Em
geral, nenhuma alteração desfavorável foi detectada nos parâmetros de segurança monitorados, em cada grupo de tratamento.
Eventos adversos foram relatados entre 11 indivíduos do grupo A e 7 indivíduos do Grupo B. Não houve diferença estatisticamente
significativa entre os grupos na incidência (p=0,463), duração (c2=13,55; df=7; p=0,06), ou distribuição de avaliação de
causalidade (p=0,4) dos eventos adversos. Os resultados deste estudo indicam claramente que não houve diferença nos resultados
do tratamento entre os dois grupos de pacientes. Ambos os tratamentos foram seguros e eficazes no tratamento dos sinais e
sintomas da otite externa como evidenciado pelas avaliações realizadas durante todo o período de tratamento. O tratamento com
Otociriax não foi inferior ao tratamento com Cipro HC® na população de pacientes avaliados neste estudo.
Abstract
This was Phase III multicenter, double-blind, randomized, comparative safety and efficacy study in parallel groups of subjects,
assessing non-inferiority between two commercially available otologic suspensions containing ciprofloxacin 2mg/mL and
hydrocortisone 10mg/mL (Otociriax and Cipro HC®) in the treatment of acute diffuse otitis externa. Following screening and
informed consent, subjects were randomly allocated into two treatment groups: Group A (treated with Otociriax) and Group B
(treated with Cipro HC®). Treatment regimen in both groups was three drops, twice daily for seven days. The primary study
endpoint was otitis cure, defined as elimination of pain, edema, and otorrhea. The secondary study endpoint was presence of side
effects. Efficacy assessments included presence and intensity of otitis externa manifestations. Safety assessments included vital
signs and physical examination, as well as adverse event monitoring. Study data analysis was performed using GraphPad Prism 5.0.
For categorical variables, we used the c2 or Fisher’s test, while continuous variables were analyzed using the ANOVA or Student’s T
test. A total of 265 subjects were randomized to treatment, with 132 subjects in Group A and 133 in Group B. There were no
statistically significant pretreatment differences between the two treatment groups (p>0.05 for all variables). All subjects presented
manifestations of acute diffuse otitis externa at pretreatment. There were statistically significant improvements (p<0.05) in each
parameter of otitis externa assessed in both treatment groups. At the end of the treatment period, 96 (82.05%) subjects in Group
A and 100 subjects (86.97%) in Group B were completely symptom-free, with no statistically significant difference between
treatment groups in symptom remission (c2=2.147; df=3; p=0.542). Overall, no unfavorable alteration was detected in the safety
parameters monitored, in either treatment group. Adverse events were reported among 11 subjects in Group A and 7 subjects in
Group B. There was no statistically significant between-group difference in incidence (p=0.463), duration (c2=13.55; df=7;
p=0.06), or distribution of causality assessment (p=0.4) of the adverse events. The results of this study clearly indicate that there
was no difference in treatment results between the two patient groups. Both treatments were safe and effective in treating the
signs and symptoms of otitis externa as evidenced by the assessments performed throughout the treatment period. Treatment with
Otociriax was non-inferior to treatment with Cipro HC® in the patient population evaluated in this study.
Introduction
The ear is divided into three parts: external, middle, and inner ear. The external ear is formed by the pinna and external auditory
meatus, at the end of this canal is the tympanic membrane. Behind the tympanic membrane lie the middle and inner ear. Otitis
externa (OE) is a type of infection affecting the external auditory canal. The warm, humid, dark environment of the ear canal
provides favorable conditions for inflammation and/or infection by bacterial or fungal species1.
Acute diffuse otitis externa is a very common condition in tropical countries, responsible for a large number of otorhinolaryngology
emergency room visits, particularly in the summer5. It is characterized by acute and diffuse inflammation of the skin covering and
the subcutaneous tissue of the outer ear. The predominant cause of OE is bacterial and the principal manifestation is otalgia, the
intensity of which may vary from mild to severe. Small quantities of mucopurulent otorrhea may also be observed, in addition to
auricular fullness, hypoacusia, and pruritus9. Physical examination often reveals hyperemia of the external ear canal, with small
quantities of mucopurulent discharge. In some case, the tympanic membrane may not be visible due to the intense edema of the
ear canal, while in other cases thickness and hyperemia of the tympanic membrane is noted, which may give a false impression of
otitis media. Painful retro and preauricular adenomegaly may also be found, in addition to edema of the tissues surrounding the
ear1,8.
Factors contributing to the pathophysiology of otitis externa include obstruction, absence of cerumen, trauma, and alteration of the
pH of the ear canal. Inflammation and skin edema lead to obstruction of adjacent structures and pruritus, which in turn favor
alterations in the quality and quantity of cerumen, epithelial migration, and changes in pH of the ear canal. As previously
mentioned, the dark, alcaline, ear canal provides a favorable breeding ground for microorganisms 10.
Excessive cleaning of the ear and/or scratching of the ear canal not only removes cerumen but also creates abrasions in the thin
layer of skin of the ear canal, allowing access of microorganisms to deeper tissue. Swimming is also an important risk factor for the
development of otitis externa 10.
Approximately 38% of otitis externa infections are by P. aeruginosa, with staphylococcal infections corresponding to approximately
25% of isolated organisms, among which S. epidermidis and S.aureus are the most common. The second largest group of
gram-positive bacteria belong to the diphtheroid family, and includes M. otitidis and M. alconae. Enterobacteriaceae and
Vibronaceae species correspond to approximately 8.5% of identified etiologic agents. In decreasing order of frequency are:
Enterobacter, Klebsiella, Serratia, Proteus, and E. coli 7.
The clinical picture of otits externa includes intense, radiating pain to the temporal and mandibular regions, sensitivity to palpation
and manipulation of the ear, loss of conductive audition and ear swelling by edema, together with external ear canal stenosis due to
accumulation of debris and secretions. Upon physical examination, the canal is erythematous and presents inflammatory infiltration
that may progress to stenosis and the presence of phlegmonosum accumulation. Purulent otorrhea, vesicles, false membranes and
crusted lesions may also be observed. In more advanced cases, fever and pre- and postauricular anterior cervical lymphadenopathy
may also be present 1,9.
Acute otitis externa can be divided into two stages, pre-inflammatory and inflammatory. The pre-inflammatory stage is associated
with mild pain, edema and swelling of the external ear, while the inflammatory stage can be subcategorized into mild, moderate,
and severe. In the mild inflammatory stage, pruritus, progressive pain, and discrete edema is observed; the outer ear canal is
unobstructed. In the moderate stage, increased pain and edema are noted and the outer ear canal is partially obstructed by edema
and secretion. The severe stage is associated with severe pain that worsens with mastigation and dislocation of the skin
surrounding the ear. The lumen of the outer ear canal is obliterated by secretion, increased edema and erythema, usually with
signs of dissemination to surrounding tissues and regional lymph nodes 9.
Acute diffuse OE is diagnosed by examination of the ear with an otoscope. During the exam, the following signs and symptoms are
noted: swelling or redness of the skin of the outer ear canal; secretion or lesions in the canal; swollen lymph nodes near the ear1.
Treatment of acute diffuse OE combines systemic and topical treatments which aim to address the symptoms presented by the
patient. Pain is treated with systemic medications, such as acetaminophen, ibuprofen, codein, and diclofenac. Topical treatment with
antibiotic ear drops is indicated in cases of localized infection in the external ear canal, without extension to neighboring areas.
Systemic antibiotic use is not recommended for uncomplicated cases 2,3,4,6,10.
In this study, we evaluated the use of two topical formulations combining antibiotic (ciprofloxacin) with a steroid (hydrocortisone) in
the treatment of acute diffuse otitis externa.
Material & Methods
This was a Phase III multicenter, double-blind, randomized, comparative safety and efficacy study in parallel groups of subjects,
assessing non-inferiority between two commercially available otologic suspensions containing ciprofloxacin 2 mg/mL and
hydrocortisone 10 mg/mL (Otociriax and Cipro HC®). The study protocol was submitted to and approved by the ethical committee
of each participating institution.
Following screening and informed consent, subjects of both genders between the ages of 1 and 70 years of age, with a clinical
diagnosis of acute otitis externa, were randomized into two treatment groups: Group A was treated with Otociriax; while subjects in
group B were treated with Cipro HC®. Treatment regimen in both groups was three drops, twice daily for seven days.
Randomization lists were generated for each study center.
Safety and efficacy assessments were carried out throughout the treatment period. Two study visits were conducted: Pretreatment
and Post-treatment. Pretreatment procedures included clinical assessment, verification of inclusion and exclusion criteria, signature
of the informed consent form and subject inclusion; subjects also received a diary containing questions to be answered during the
treatment period, returned at the end of the study. At treatment day 3 and treatment day 6, a member of the clinical study team
telephoned the patient to inquire about treatment compliance, occurrence of adverse events, and symptom severity. The
Post-treatment visit took place between the 8th and 11th day following treatment initiation. Subjects returned to the study center
for clinical assessments of safety and efficacy and returned study medication and diaries. Use of concomitant medications was
monitored throughout the study period.
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The primary study endpoint was otitis cure, defined as elimination of pain, edema, and otorrhea. The secondary study endpoint was
identification of side effects caused by use of the study medication. Efficacy assessments included presence and intensity (mild,
moderate, or severe) of otitis externa manifestations: dermal inflammation, otalgia, pain on compression, otorrhea, hypoacusia,
pruritus, hyperemia of the ear canal, edema of the ear canal, adenomegalia, edema of surrounding tissues, and fever. Safety
assessments included vital signs and physical examination, as well as adverse event monitoring (occurrence, severity, duration,
resolution, and relation to study drug).
Data from each center were tabulated, merged in a single database, and unblinded after the end of the study treatment period.
Results were statistically analyzed using the software GraphPad Prism 5.0. Overall clinical efficacy and tolerability were analyzed
via comparison of the results of each assessment in relation to pretreatment values, within and between treatment groups. For
categorical variables, we used the c2 or Fisher’s test, while continuous variables were analyzed using the ANOVA or Student’s T
test.
Figure 1. Flowchart  of subject s through the study.
Results
A total of 265 subjects were randomized to treatment, with 132 subjects in Group A and 133 in Group B. Figure 1 shows the flow of
subjects throughout the study. There were no statistically significant pretreatment differences between the two treatment groups in
distribution of gender, age, physical exam results, weight, vital signs, temperature, and otitis manifestations (p>0.05 for all
variables). Table 1 summarizes the demographic and pretreatment characteristics of the study population.
All subjects presented manifestations of acute diffuse otitis externa at pretreatment. The assessments of otitis of each patient group
at Pre- and Post-Treatment are summarized in Table 2. There were statistically significant improvements (p<0.05) in each
parameter assessed in both treatment groups.
There were no statistically significant between-group differences during the first and second telephone contacts which took place at
treatment day 3 and treatment day 6 (p>0.05 for all assessments). At Telephone Contact 1, symptoms were absent among 22
subjects in Group A and 27 subjects in Group B. The distribution of subject-reported symptom intensity during Telephone Contact 1
was reported as "Minimal" among 51/50 subjects in treatment groups A and B, respectively, "Moderate" among 41/46 subjects, and
"Intense" among 4/3 subjects in treatment groups A and B, respectively. At Telephone Contact 2, 75 subjects in Group A and 68
subjects in Group B reported absence of symptoms. The distribution of subject-reported symptom intensity was reported as
"Minimal" among 37/38 subjects in treatment groups A and B, respectively, "Moderate" among 6/11 subjects, and "Intense" among
1/0 subjects in treatment groups A and B, respectively.
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At the end of the treatment period, 96 (82.05%) subjects in Group A and 100 subjects (86.97%) in Group B were completely
symptom-free, with no statistically significant difference between treatment groups in symptom remission (c2=2.147; df=3;
p=0.542) (Figure 2).
The results of the safety evaluations performed during the study are summarized in Table 3. Overall, no unfavorable alteration was
detected in the safety parameters monitored, in either treatment group. Adverse events were reported among subjects in both
treatment groups, with 11 subjects in Group A and 7 subjects in Group B reporting occurrence of adverse events. The adverse
events recorded during the treatment period are summarized in Table 4. There was no stainitiated prior to obtaining culture results
in most instances, given that treatment is geared toward the most commonly identified bacterial pathogens found among patients
with otitis externa10,11. Topical treatment provides the advantage of delivering a higher drug dosage directly to the site of
infection independently of systemic administration, resulting in a more favorable safety profile with a lower risk of adverse effects.
The addition of hydrocortisone to the antibiotic in an ear drop formulation offers the potential for significant reduction of treatment
time to pain relief 12.
The results of this study clearly indicate that there was no difference in treatment results between the two patient groups. Both
treatments were equally safe and effective in treating the signs and symptoms of otitis externa as evidenced by the assessments
performed throughout the treatment period. Treatment with Otociriax was non-inferior to treatment with Cipro HC® in the patient
population evaluated in this study.
Figure 2. Assessment  of symptom remission
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